Hannah Grace Abraham1,2, Yaoxuan Xia3, Bhramar Mukherjee3, Sofia Diana Merajver4,5,6. 1. University of Michigan Medical School, Ann Arbor, MI, USA. 2. University of Michigan Rogel Cancer Center, 1500 E Medical Drive 7217, Ann Arbor, MI, 48109, USA. 3. School of Public Health, University of Michigan, Ann Arbor, MI, USA. 4. University of Michigan Medical School, Ann Arbor, MI, USA. smerajve@umich.edu. 5. University of Michigan Rogel Cancer Center, 1500 E Medical Drive 7217, Ann Arbor, MI, 48109, USA. smerajve@umich.edu. 6. School of Public Health, University of Michigan, Ann Arbor, MI, USA. smerajve@umich.edu.
Abstract
PURPOSE: Inflammatory breast cancer (IBC) is an aggressive variant characterized by erythema, edema, and "peau d'orange" of the skin progressing within 6 months. We assessed the incidence and survival of IBC in the US over four decades. METHODS: Using SEER*Stat, a case list of IBC patients diagnosed between 1973 and 2015 (n = 29,718) was extracted from SEER 18 registries by using a combination of morphology, stage, and extent of disease criteria. M1 and M0 patients were included. Age-adjusted incidence rates, relative survival rates, and mean survival time were calculated. Significance was determined as non-overlapping 95% confidence intervals. RESULTS: The overall incidence of IBC from 1973 to 2015 is 2.76 (2.73, 2.79) cases per 100,000 people, with white patients having an incidence rate of 2.63 (2.60, 2.67), black patients 4.52 (4.39, 4.65), and patients of other race 1.84 (1.76, 1.93). The overall IBC relative 5-year survival rate is 40.5% (39.0%, 42.0%), 42.5% (40.7%, 44.3%), and 29.9% (26.6%, 33.3%) for white patients and black patients, respectively. Patients diagnosed in 1978-1982 have a mean survival time of 62.3 (52.0, 72.6) months, while those diagnosed in 2008-2012 have mean survival time of 99.4 (96.4, 102.4) months. There is no significant difference in survival time between T4D patients and patients with other T staging and extent of disease coding consistent with clinical IBC presentation. CONCLUSIONS: IBC survival has increased over four decades. Despite the improvement in survival for all racial groups, a persistent survival disparity that has not narrowed over two decades remains between white and black patients.
PURPOSE: Inflammatory breast cancer (IBC) is an aggressive variant characterized by erythema, edema, and "peau d'orange" of the skin progressing within 6 months. We assessed the incidence and survival of IBC in the US over four decades. METHODS: Using SEER*Stat, a case list of IBC patients diagnosed between 1973 and 2015 (n = 29,718) was extracted from SEER 18 registries by using a combination of morphology, stage, and extent of disease criteria. M1 and M0 patients were included. Age-adjusted incidence rates, relative survival rates, and mean survival time were calculated. Significance was determined as non-overlapping 95% confidence intervals. RESULTS: The overall incidence of IBC from 1973 to 2015 is 2.76 (2.73, 2.79) cases per 100,000 people, with white patients having an incidence rate of 2.63 (2.60, 2.67), black patients 4.52 (4.39, 4.65), and patients of other race 1.84 (1.76, 1.93). The overall IBC relative 5-year survival rate is 40.5% (39.0%, 42.0%), 42.5% (40.7%, 44.3%), and 29.9% (26.6%, 33.3%) for white patients and black patients, respectively. Patients diagnosed in 1978-1982 have a mean survival time of 62.3 (52.0, 72.6) months, while those diagnosed in 2008-2012 have mean survival time of 99.4 (96.4, 102.4) months. There is no significant difference in survival time between T4D patients and patients with other T staging and extent of disease coding consistent with clinical IBC presentation. CONCLUSIONS: IBC survival has increased over four decades. Despite the improvement in survival for all racial groups, a persistent survival disparity that has not narrowed over two decades remains between white and black patients.
Entities:
Keywords:
Disparities; Incidence; Inflammatory breast cancer; Survival
Authors: Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine Journal: J Natl Cancer Inst Date: 2005-07-06 Impact factor: 13.506
Authors: Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver Journal: Breast Cancer Res Treat Date: 2012-06-26 Impact factor: 4.872
Authors: D J P van Uden; H W M van Laarhoven; A H Westenberg; J H W de Wilt; C F J M Blanken-Peeters Journal: Crit Rev Oncol Hematol Date: 2014-10-16 Impact factor: 6.312
Authors: J Cortes; V Calvo; N Ramírez-Merino; J O'Shaughnessy; A Brufsky; N Robert; M Vidal; E Muñoz; J Perez; S Dawood; C Saura; S Di Cosimo; A González-Martín; M Bellet; O E Silva; D Miles; A Llombart; J Baselga Journal: Ann Oncol Date: 2011-10-04 Impact factor: 32.976
Authors: Bryan Goldner; Carolyn E Behrendt; Hans F Schoellhammer; Byrne Lee; Steven L Chen Journal: Ann Surg Oncol Date: 2013-12-24 Impact factor: 5.344
Authors: Jill K Schinkel; Shelia Hoar Zahm; Ismail Jatoi; Katherine A McGlynn; Christopher Gallagher; Catherine Schairer; Craig D Shriver; Kangmin Zhu Journal: Cancer Causes Control Date: 2014-05-17 Impact factor: 2.506
Authors: Muthana Al Abo; Larisa Gearhart-Serna; Steven Van Laere; Jennifer A Freedman; Steven R Patierno; Eun-Sil Shelley Hwang; Savitri Krishnamurthy; Kevin P Williams; Gayathri R Devi Journal: NPJ Breast Cancer Date: 2022-06-13
Authors: Astrid Zayas-Santiago; Michelle M Martínez-Montemayor; Jadier Colón-Vázquez; Gabriela Ortiz-Soto; Jose G Cirino-Simonet; Mikhail Inyushin Journal: FEBS Open Bio Date: 2021-10-26 Impact factor: 2.693
Authors: Emilly S Villodre; Xiaoding Hu; Richard Larson; Pascal Finetti; Kristen Gomez; Wintana Balema; Shane R Stecklein; Ginette Santiago-Sanchez; Savitri Krishnamurthy; Juhee Song; Xiaoping Su; Naoto T Ueno; Debu Tripathy; Steven Van Laere; François Bertucci; Pablo Vivas-Mejía; Wendy A Woodward; Bisrat G Debeb Journal: Mol Oncol Date: 2021-08-27 Impact factor: 6.603